|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Leukemia | |||||
| Lymphoma | |||||
| Sarcoma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Lymphoma, Non-Hodgkin | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Lymphatic Diseases | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| 4 | Interventions listed in this trial | ||||
| estramustine phosphate sodium | |||||
| paclitaxel | |||||
| vinorelbine ditartrate | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Estramustine | |||||
| Vinblastine | |||||
| Vinorelbine | |||||
| 6 | More general drug interventions related to this trial | ||||
| Alkylating Agents | |||||
| Antimitotic Agents | |||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Alkylating | |||||
| Antineoplastic Agents, Hormonal | |||||
| Antineoplastic Agents, Phytogenic | |||||
| Mitosis Modulators | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| Tubulin Modulators | |||||
| 7 | Sponsors listed in this trial | ||||
| New York University School of Medicine | |||||
| National Cancer Institute (NCI) | |||||